PRPO — Precipio, Inc.

Summary of Precipio (PRPO) Q2 2025 Earnings Call

1. Key Financial Results and Metrics

• Revenue Growth: Q2 2025 saw continued revenue growth with the Pathology Services division growing at an annualized rate of approximately 70%. Products division revenue increased by 23% quarter-over-quarter, indicating nearly 100% annualized growth.
• Gross Margins: Overall gross margins improved from 39% to 43%. However, there was a slight decline in product gross margin, expected to reverse in the next quarter.
• Cash Flow: The company made strategic investments in laboratory space and equipment, which had a modest impact on the path to breakeven. Management is confident in reaching breakeven in 2025 without needing additional capital.

2. Strategic Updates and Business Highlights

• Pathology Services: This division continues to generate consistent revenue and cash flow, with a record revenue month exceeding $2 million in July (unaudited). The division is self-supportive and generates samples for the Products division.
• Products Division: Recent operational challenges have been resolved, allowing for revenue recovery from previously affected customers. A new optional send-out continuity program has been introduced to ensure uninterrupted service for customers during disruptions.
• Distributor Relationships: The company is focusing on building relationships with distributors to enhance market penetration, leveraging their established connections to accelerate customer acquisition.

3. Forward Guidance and Outlook

• Q3 Expectations: A strong pipeline of new customers is anticipated, with continued growth expected in Q3. The company aims to maintain momentum and further improve service delivery and customer satisfaction.
• Long-term Goals: Management projects gross margins in the Pathology Services division to stabilize around 50% by 2026.

4. Bad News, Challenges, or Points of Concern

• Operational Challenges: Past disruptions due to equipment failures and staffing issues had negatively impacted revenue, though these issues are reportedly resolved.
• Market Perception: There is uncertainty regarding the sustainability of recent stock price increases, which tripled in the last quarter. Management acknowledges that while performance has improved, market behavior remains unpredictable.

5. Notable Q&A Insights

• Warrant Conversion: Management explained a recent warrant conversion strategy that minimized dilution while still raising capital. This involved a mix of standard and cashless warrant exercises to control share issuance.
• Investor Interest: There has been a notable increase in inquiries from investors, attributed to improved company performance and a more proactive approach to communicating the company’s story.
• Future Engagement: The company plans to increase its visibility in the market through participation in investor conferences and other public engagements, aiming to build on the momentum of recent performance improvements.

Overall, Precipio is experiencing positive growth trends, particularly in its Pathology Services division, while strategically addressing past operational challenges and enhancing customer relationships. The outlook remains optimistic, with management focused on achieving breakeven and further improving financial performance.